Xencor Inc has appointed RSM MSCBA alumnus Bart Cornelissen as chief financial officer to support its clinical-stage pipeline of engineered antibodies for the treatment of cancer and other serious diseases.
RSM uses cookies to measure website statistics, enable social media sharing and for marketing purposes.
By clicking accept cookies or by continuing to use this website, you are giving consent for us to set cookies when visiting this website.
See our cookie policy for more information about cookies and how to adjust your cookie settings.